Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
EndoPredict results reflected tumor response to neoadjuvant therapy
Publish date:
January 2, 2018
REPORTING FROM SABCS 2017
SOURCE:
Dubsky P et al. SABCS 2017
Abstract GS6-04
.
op@frontlinemedcom.com
Pages
« first
1
2
Recommended Reading
High rate of arm morbidity in young breast cancer survivors
MDedge Hematology and Oncology
Postmenopausal women who shed pounds see lower breast cancer risk
MDedge Hematology and Oncology
Path CR signals good outcomes in treated high-risk breast cancers
MDedge Hematology and Oncology
DCIS risk signature is validated in SweDCIS population
MDedge Hematology and Oncology
ERBB2 expression predicts pCR in HER2+ breast cancer
MDedge Hematology and Oncology
Axillary node dissection can be avoided with limited SLN involvement
MDedge Hematology and Oncology
Lapatinib plus trastuzumab improves outcomes in HER2+ breast cancer
MDedge Hematology and Oncology
Pertuzumab approved for HER2-positive breast cancer
MDedge Hematology and Oncology
Enzalutamide plus exemestane improves PFS in HR+ breast cancer subset
MDedge Hematology and Oncology
Wider margins may reduce recurrence risk in early breast cancer
MDedge Hematology and Oncology
Breast Cancer
All Specialties
